No CrossRef data available.
Article contents
Opportunists and Opportunities: The 2010 SHEA Lecture
Published online by Cambridge University Press: 02 January 2015
Abstract
My experience as a hospital epidemiologist at the National Institutes of Health Clinical Center has underscored the importance of aggressively managing infection with opportunistic pathogens and of taking advantage of opportunities as they arise (most often as crises). I review selected aspects of my career and use these as examples of the opportunists and opportunities now facing healthcare epidemiology.
- Type
- Supplement Article
- Information
- Infection Control & Hospital Epidemiology , Volume 31 , Issue S1: Papers from the Fifth Decennial International Conference on Healthcare-Associated Infections , November 2010 , pp. S66 - S69
- Copyright
- Copyright © The Society for Healthcare Epidemiology of America 2010
References
1.Gallin, JI. John, I. Gallin, MD, Director, NIH Clinical Center. J Investig Med 2007;55(4):160–162.Google ScholarPubMed
2.Beekmann, SE, Vlahov, D, Koziol, DE, McShalley, ED, Schmitt, JM, Henderson, DK. Temporal association between implementation of universal precautions and a sustained, progressive decrease in percutaneous exposures to blood. Clin Infect Dis 1994;18(4):562–569.CrossRefGoogle Scholar
3.Fahey, BJ, Koziol, DE, Banks, SM, Henderson, DK. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. Am J Med 1991;90(2):145–153.CrossRefGoogle ScholarPubMed
4.Henderson, DK, Fahey, BJ, Willy, ME, Schmitt, JM, Carey, K, Koziol, DE. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: a prospective evaluation. Ann Intern Med 1990;113:740–746.CrossRefGoogle ScholarPubMed
5.Henderson, DK, Saah, AJ, Zak, BJ, et al.Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers. Ann Intern Med 1986;104(5):644–647.Google Scholar
6.Centers for Disease Control and Prevention. Recommendations for prevention of HIV transmission in health-care settings. MMWR Morb Mortal Wkly Rep 1987;36(Suppl 2):1S–18S.Google Scholar
7.Mitsuya, H, Jarrett, RF, Matsukura, M, et al.Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Natl Acad Sci 1987;84(7):2033–2037.CrossRefGoogle Scholar
8.Henderson, DK. Postexposure treatment of HIV—embracing risk for safety's sake. N Engl J Med 1997;337(21):1542–1543.CrossRefGoogle Scholar
9.Henderson, DK. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 1999;281(10):931–936.Google Scholar
10.Henderson, DK. HIV postexposure prophylaxis in the 21st century. Emerg Infect Dis 2001;7(2):254–258.Google Scholar
11.Henderson, DK, Gerberding, JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis 1989;160(2):321–327.CrossRefGoogle Scholar
12.Lee, LM, Henderson, DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001;24(8):587–597.CrossRefGoogle ScholarPubMed
13.Centers for Disease Control and Prevention. Public Health Service statement on management of occupational exposure to human immuno-deficiency virus, including considerations regarding zidovudine postexposure use. MMWR Recomm Rep 1990;39(RR-1):1–14.Google Scholar
14.Cardo, DM, Culver, DH, Ciesielski, CA, et al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337(21):1485–1490.Google Scholar